Vimarsana
Biggest News Aggregation in the World

Page 11 - Sci Capital News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Sci Capital. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Sci Capital Today - Breaking & Trending Today

Lifesci Acquisition II : Science 37, the Operating System for Agile Clinical Trials, Closes Business Combination with LifeSci Acquisition II Corp. and Will Begin Trading on Nasdaq as SNCE - Vimarsana News

Lifesci Acquisition II : Science 37, the Operating System for Agile Clinical Trials, Closes Business Combination with LifeSci Acquisition II Corp. and Will Begin Trading on Nasdaq as SNCE

Science 37, the Operating System for Agile Clinical Trials, Closes Business Combination with LifeSci Acquisition II Corp. and Will Begin Trading on Nasdaq as SNCE ...

Investegate |RTW Venture Fund Ltd Announcements | RTW Venture Fund Ltd: Portfolio Company Update: Pyxis IPO - Vimarsana News

Investegate |RTW Venture Fund Ltd Announcements | RTW Venture Fund Ltd: Portfolio Company Update: Pyxis IPO

Investegate announcements from RTW Venture Fund Ltd, Portfolio Company Update: Pyxis IPO

Celldex Therapeutics Announces Pricing of Upsized $250 Million Public Offering of Common Stock - Vimarsana News

Celldex Therapeutics Announces Pricing of Upsized $250 Million Public Offering of Common Stock

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Celldex Therapeutics Announces Pricing of Upsized $250 Million Public Offering of Common Stock Celldex Therapeutics, Inc.July 14, 2021 GMT HAMPTON, N.J., July 13, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced the pricing of an underwritten public offering of 5,952,381 shares of its common stock at a public offering price of $42.00 per share. In connection with the offering, Celldex has granted the underwriters a 30-day option ...

Source: apnews.com
Celldex Therapeutics Announces Pricing of Upsized $250 Million Public Offering of Common Stock - Press Release - Vimarsana News

Celldex Therapeutics Announces Pricing of Upsized $250 Million Public Offering of Common Stock - Press Release

HAMPTON, N.J., July 13, 2021 (GLOBE NEWSWIRE) — Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (NASDAQ:CLDX) today announced the pricing of an underwritten public offering of 5,952,381 shares of its common stock at a public offering price of $42.00 per share. In connection with the offering, Celldex has granted the underwriters a 30-day option to purchase up to an additional 892,857 shares of common stock at the public offering price, less underwriting discounts and commissions. Jefferies, SVB Leerink, Guggenheim Securities and Cantor are acting as the joint book-running ma...

Celldex Therapeutics Announces Pricing of Upsized $250 - Vimarsana News

Celldex Therapeutics Announces Pricing of Upsized $250

Celldex Therapeutics Announces Pricing of Upsized $250 Million Public Offering of Common Stock July 13, 2021 20:30 ET | Source: Celldex Therapeutics, Inc. Celldex Therapeutics, Inc. Needham Heights, Massachusetts, UNITED STATES HAMPTON, N.J., July 13, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced the pricing of an underwritten public offering of 5,952,381 shares of its common stock at a public offering price of $42.00 per share. In connection with the offering, Celldex has ...